Inhibitory Effects of Statins on Expression of Immediate-Early 1 Protein of Human Cytomegalovirus in Virus-infected Cells

Journal of Experimental and Clinical Medicine(Taiwan)

Volumn 5, Issue 5, 2013, Pages 187-193

  Sadanari, Hidetaka ^a   Murayama, Tsugiya ^a   Zheng, Xin ^a,b   Yamada, Rie ^a   Matsubara, Keiko ^a   Yoshida, Haruno ^c   Takahashi, Takashi ^c  

^a HOKURIKU UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

Author keywords

Gene transfected cells; Human cytomegalovirus; Immediate early 1 protein; Statins; Virus infected cells

Indexed keywords

COMPACTIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMEDIATE EARLY 1 PROTEIN; IMMEDIATE EARLY PROTEIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; ENHANCER REGION; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMEDIATE EARLY 1 GENE; IMMEDIATE EARLY GENE; INTERNALIZATION; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; ULTRAVIOLET IRRADIATION; VIRUS INHIBITION;

EID: 84885848932     PISSN: 18783317     EISSN: 18783325     Source Type: Journal    
DOI: 10.1016/j.jecm.2013.08.001     Document Type: Article

References (28)

1. Britt W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr Top Microbiol Immunol 2008, 325:417-470.
2. Dollard S.C., Grosse S.D., Ross D.S. New estimates of the prevalence of neurological and sensory sequelae and mortality associated with congenital cytomegalovirus infection. Rev Med Virol 2007, 17:355-363.
3. Adler S.P., Nigro G., Pereira L. Recent advances in the prevention and treatment of congenital cytomegalovirus infections. Semin Perinatol 2007, 31:10-18.
4. Sissons J.G., Carmichael A.J. Clinical aspects and management of cytomegalovirus infection. JInfect 2002, 44:78-83.
5. Graham S.M. HIV-related pulmonary disorders: practice issues. Ann Trop Paediatr 2007, 27:243-252.
6. Popović M., Smiljanić K., Dobutović B., Syrovets T., Simmet T., Isenović E.R. Human cytomegalovirus infection and atherothrombosis. JThromb Thrombolysis 2012, 33:160-172.
7. Suzuki J., Koga N., Kosuge H., Ogawa M., Haraguchi G., Maejima Y., Saiki H., et al. Pitavastatin suppresses acute and chronic rejection in murine cardiac allografts. Transplantation 2007, 83:1093-1097.
8. Nie C., Yang D., Liu G., Dong D., Ma Z., Fu H., Zhao Z., et al. Statins induce immunosuppressive effect on heterotopic limb allografts in rat through inhibiting T cell activation and proliferation. Eur J Pharmacol 2009, 602:168-175.
9. Takano F., Bi C., Ishigaki Y., Yoshida H., Sakurada C., Takahashi T. Anticholesteremic agents, statins, modulate monocyte activation in cultured human THP-1 cells. Pharmacometrics 2013, 84:75-81.
10. Potena L., Frascaroli G., Grigioni F., Lazzarotto T., Magnani G., Tomasi L., Coccolo F., et al. Hydroxymethyl-glutaryl coenzyme a reductase inhibition limits cytomegalovirus infection in human endothelial cells. Circulation 2004, 109:532-536.
11. Murayama T., Bi C., Li Y., Ishigaki Y., Takano F., Takegami T., Ohta T., et al. Inhibitory effects of statins on cytomegalovirus production in human cells: comprehensive analysis of gene expression profiles. JExp Clin Med 2011, 3:40-45.
12. Furukawa T., Fioretti A., Plotkin S. Growth characteristics of cytomegalovirus in human fibroblasts with demonstration of protein synthesis early in viral replication. JVirol 1973, 11:991-997.
13. Murayama T., Li Y., Takahashi T., Yamada R., Matsubara K., Tsuchida Y., Zheng X., et al. Anti-cytomegalovirus effects of tricin are dependent on CXCL11. Microbes Infect 2012, 14:1086-1092.
14. Duclos H., Elfassi E., Michelson S., Arenzana-Seisdedos F., Hazan U., Munier A., Virelizier J.L. Cytomegalovirus infection and trans-activation of HIV-1 and HIV-2 LTRs in human astrocytoma cells. AIDS Res Hum Retroviruses 1989, 5:217-224.
15. Sadanari H., Tanaka J., Li Z., Yamada R., Matsubara K., Murayama T. Proteasome inhibitor differentially regulates expression of the major immediate early genes of human cytomegalovirus in human central nervous system-derived cell lines. Virus Res 2009, 142:68-77.
16. Jacobs J.P., Jones C.M., Baille J.P. Characteristics of a diploid cell designated MRC-5. Nature 1970, 227:168-170.
17. Sadanari H., Yamada R., Tanaka J., Murayama T., Ohnishi K., Matsubara K., Fukuda S. The effect of cyclic AMP on expression of the major immediate-early genes and replication of human cytomegalovirus in human central nervous system cell lines. Arch Virol 1999, 144:1015-1025.
18. Murayama T., Mukaida N., Sadanari H., Yamaguchi N., Khabar K.S., Tanaka J., Matsushima K., et al. The immediate early gene 1 product of human cytomegalovirus is sufficient for up-regulation of interleukin-8 gene expression. Biochem Biophys Res Commun 2000, 279:298-304.
19. He R., Sandford G., Hayward G.S., Burns W.H., Posner G.H., Forman M., Arav-Boger R. Recombinant luciferase-expressing human cytomegalovirus (CMV) for evaluation of CMV inhibitors. Virol J 2011, 8:40. http://dx.doi.org/10.1186/1743-422X-8-40.
20. Moses S., Malathi J., Singha N.R., Bagyalakshmi R., Madhavan H.N. Determination of human cytomegalovirus pp65 antigenemia among renal transplant patients. Indian J Nephrol 2012, 22:347-352.
21. Kitagawa R., Takahashi Y., Takahashi M., Imazu H., Yasuda M., Sadanari H., Tanaka J. Hexamethylene bisacetamide can convert nonpermissive human cells to a permissive state for expressing the major immediate-early genes of human cytomegalovirus by up-regulating NF-kappaB activity. Virology 2009, 383:195-206.
22. Cantrell S.R., Bresnahan W.A. Human cytomegalovirus (HCMV) UL82 gene product (pp71) relieves hDaxx-mediated repression of HCMV replication. JVirol 2006, 80:6188-6191.
23. Woodhall D.L., Groves I.J., Reeves M.B., Wilkinson G., Sinclair J.H. Human Daxx-mediated repression of human cytomegalovirus gene expression correlates with a repressive chromatin structure around the major immediate early promoter. JBiol Chem 2006, 281:37652-37660.
24. Hwang J., Kalejta R.F. Proteasome-dependent, ubiquitin-independent degradation of Daxx by the viral pp71 protein in human cytomegalovirus-infected cells. Virology 2007, 367:334-338.
25. Noble S., Faulds D. Ganciclovir. An update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 1998, 56:115-146.
26. Deray G., Martinez F., Katlama C., Levaltier B., Beaufils H., Danis M., Rozenheim M., et al. Foscarnet nephrotoxicity: mechanism, incidence and prevention. Am J Nephrol 1989, 9:316-321.
27. Ho E.S., Lin D.C., Mendel D.B., Cihlar T. Cytotoxicity of antiviral nucleotides adefovir and cidofovir is induced by the expression of human renal organic anion transporter 1. JAm Soc Nephrol 2000, 11:383-393.
28. De Clercq E. New inhibitors of human cytomegalovirus (HCMV) on the horizon. JAntimicrob Chemother 2003, 51:1079-1083.